Robert Wasserman
Stock Analyst at Benchmark
(3.69)
# 821
Out of 4,734 analysts
110
Total ratings
51.58%
Success rate
6.62%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Reiterates: Buy | $135 | $111.89 | +20.65% | 10 | Dec 23, 2024 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $26.14 | +14.77% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $1.59 | +403.14% | 6 | Nov 19, 2024 | |
| OABI OmniAb | Reiterates: Buy | $8 | $3.21 | +149.22% | 7 | Nov 14, 2024 | |
| NEPH Nephros | Reiterates: Speculative Buy | $5 | $1.60 | +212.50% | 3 | Nov 12, 2024 | |
| EBS Emergent BioSolutions | Maintains: Buy | $8 → $12 | $9.88 | +21.46% | 17 | Nov 7, 2024 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $2.97 | - | 5 | Nov 5, 2024 | |
| CDXS Codexis | Reiterates: Hold | n/a | $5.00 | - | 7 | Nov 4, 2024 | |
| ITGR Integer Holdings | Reiterates: Buy | $140 | $141.00 | -0.71% | 9 | Oct 25, 2024 | |
| IPA ImmunoPrecise Antibodies | Maintains: Speculative Buy | $5 → $3 | $0.53 | +465.93% | 5 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $75.83 | +25.28% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $54.80 | +9.49% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $160.51 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $12 | $2.76 | +334.78% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $38.54 | +16.76% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.42 | +16.96% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.81 | +395.05% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $1.87 | +3,910.70% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $238.36 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $559.65 | +3.64% | 1 | Jul 16, 2021 |
Ligand Pharmaceuticals
Dec 23, 2024
Reiterates: Buy
Price Target: $135
Current: $111.89
Upside: +20.65%
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $26.14
Upside: +14.77%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $1.59
Upside: +403.14%
OmniAb
Nov 14, 2024
Reiterates: Buy
Price Target: $8
Current: $3.21
Upside: +149.22%
Nephros
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $1.60
Upside: +212.50%
Emergent BioSolutions
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $9.88
Upside: +21.46%
AbCellera Biologics
Nov 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.97
Upside: -
Codexis
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $5.00
Upside: -
Integer Holdings
Oct 25, 2024
Reiterates: Buy
Price Target: $140
Current: $141.00
Upside: -0.71%
ImmunoPrecise Antibodies
Aug 14, 2024
Maintains: Speculative Buy
Price Target: $5 → $3
Current: $0.53
Upside: +465.93%
Aug 13, 2024
Reiterates: Buy
Price Target: $95
Current: $75.83
Upside: +25.28%
Aug 8, 2024
Reiterates: Buy
Price Target: $60
Current: $54.80
Upside: +9.49%
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $160.51
Upside: -
Jul 11, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $2.76
Upside: +334.78%
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $38.54
Upside: +16.76%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.42
Upside: +16.96%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.81
Upside: +395.05%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.87
Upside: +3,910.70%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $238.36
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $559.65
Upside: +3.64%